# South Korea Radiopharmaceuticals Market > South Korea Radiopharmaceuticals Market Research Report By Type (Diagnostic, Therapeutic) and By Application (Neurology, Cardiology, Oncology, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.81% - **2024:** $ 1,250 Million - **2025:** USD Million - **2035:** $ 3,500 Million - **Key Players:** KHIDI, Posco Holdings, Ilyang Pharmaceutical, PTG Energy, Daiichi Sankyo, Taejoon Pharmaceutical, Korea Atomic Energy Research Institute, Alphamed, Philips Healthcare, Korea Radioisotope Association, Nautilus Biomedical, Hanmi Pharmaceutical, Bioscience Institute, Lantheus, CURE Pharmaceuticals **Report ID:** MRFR/Pharma/42236-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** July 02, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-radiopharmaceuticals-market-43909 --- ## Market Summary ## **South Korea Radiopharmaceuticals Market Overview** As per MRFR analysis, the South Korea Radiopharmaceuticals Market Size was estimated at 0.16 (USD Billion) in 2023. The South Korea Radiopharmaceuticals Market Industry is expected to grow from 0.18(USD Billion) in 2024 to 0.42 (USD Billion) by 2035. The South Korea Radiopharmaceuticals Market CAGR (growth rate) is expected to be around 8.18% during the forecast period (2025 - 2035). ## **Key South Korea Radiopharmaceuticals Market Trends Highlighted** South Korea's radiopharmaceutical market is currently experiencing significant growth, primarily driven by the increasing incidence of chronic diseases and the rising demand for accurate diagnostic procedures. The South Korean healthcare system places a strong emphasis on advanced medical technologies, which fuels the adoption of radiopharmaceuticals. Furthermore, government support through funding initiatives for research and development is enhancing innovation in this sector.  Opportunities exist in the expansion of high-specificity radiopharmaceuticals that provide targeted therapies, especially in treating cancers, which align with South Korea's focus on precision medicine.There is a recent shift towards using artificial intelligence and machine learning in conjunction with radiopharmaceuticals for more precise imaging and treatment results. This shift is most likely to enable more efficient operations in hospitals and imaging centers.  Additionally, this is facilitated by the growing collaboration between universities and the pharmaceutical industry for new radiopharmaceuticals, which is anticipated to broaden the market scope. In addition, the increasingly aged South Korean population raises the need and usage of nuclear medicine, which can help grow the market. The established legislation in the country guarantees the safety and effectiveness of new products, which enhances foreign investment in radiopharmaceuticals. There is an expected shift in the South Korean market for radiopharmaceuticals as providers shift towards more personalized treatment options. In summary, the combination of government initiatives, uptake of new technologies, and demographic changes are driving factors towards Shaping this market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Radiopharmaceuticals Market Drivers** ### Increasing Incidence of Cancer The South Korea Radiopharmaceuticals Market Industry is significantly driven by the increasing incidence of cancer among the population. According to the Korea Central Cancer Registry, the number of cancer patients in South Korea has risen dramatically, with an estimated 240,000 new cancer cases reported in 2020. This represents a continuous upward trend, with projections indicating that the number of cases could reach 330,000 by 2025. As cancer diagnosis and treatment increasingly rely on advanced imaging techniques utilizing radiopharmaceuticals, institutions like the Korean Society of Nuclear Medicine are actively promoting the development and application of these technologies to improve patient outcomes.This escalating demand for precise diagnostic measures is likely to fuel growth in the South Korea Radiopharmaceuticals Market. ### Technological Advancements in Radiopharmaceuticals Rapid advancements in radiopharmaceutical technology are another key driver for the South Korea Radiopharmaceuticals Market Industry. Initiatives by the Ministry of Health and Welfare to encourage innovation among domestic pharmaceutical companies have led to the creation of more sophisticated radiopharmaceuticals, allowing for enhanced imaging and therapeutic applications. Recent developments in targeted therapy and theranostics, where diagnostics and therapy converge, are expected to revolutionize cancer treatment in the country.With research institutions like the Korean Institute of Radiological and Medical Sciences contributing to these advancements, the market is poised for significant growth as new products enter the market. ### Government Initiatives Supporting Nuclear Medicine The South Korean government has been increasingly supporting the development of nuclear medicine through various initiatives aimed at improving healthcare access and treatment options. The government's healthcare policy emphasizes the need to enhance diagnostic capabilities and integrate advanced medical technologies into the healthcare system. For instance, the Korean government's 5-Year Plan for Nuclear Medicine (2019-2023) allocates significant resources towards research, development, and training in nuclear medicine.As a result, the South Korea Radiopharmaceuticals Market Industry stands to benefit from improved infrastructure and funding, driving growth in the sector. ## **South Korea Radiopharmaceuticals Market Segment Insights** ### **Radiopharmaceuticals Market Type Insights** The South Korea Radiopharmaceuticals Market is characterized by its significant segmentation into Diagnostic and Therapeutic categories, each playing a crucial role in the overall healthcare landscape. Diagnostic radiopharmaceuticals are widely utilized in various imaging techniques, helping healthcare professionals identify diseases at early stages, which is vital for effective treatment initiation. This category typically includes compounds designed for nuclear imaging, facilitating the visualization of physiological and biochemical processes in living organisms.  The increasing prevalence of chronic diseases in South Korea has necessitated enhanced diagnostic tools, pushing the demand for radiopharmaceuticals in imaging procedures. Meanwhile, the Therapeutic segment of the South Korea Radiopharmaceuticals Market represents an equally vital area, focusing on treating ailments through targeted radionuclide therapy. Such therapies leverage the unique properties of radioactive isotopes to deliver precise doses of radiation to diseased cells, often resulting in lesser side effects compared to traditional treatment modalities.  The growth of personalized medicine has catalyzed the development and acceptance of therapeutic radiopharmaceuticals, particularly for oncology applications. With the rise in cancer diagnoses in South Korea, the significance of these products continues to grow, driven by the efficacy of radiopharmaceuticals in providing effective treatment options. Moreover, both segments are supported by robust advancements in radiochemistry and nuclear medicine technologies, positioning South Korea as a key player in the global radiopharmaceuticals landscape. Government initiatives promoting research and development alongside collaborative efforts between academic institutions and pharmaceutical companies are further driving innovations within the market.  South Korea's strategic investments in healthcare infrastructure, coupled with increasing awareness about the advantages of radiopharmaceuticals in diagnostic and therapeutic settings, offer a promising trajectory for growth in the coming years. The factors above collectively contribute to a dynamic environment for the South Korea Radiopharmaceuticals Market, making it an area of substantial interest and opportunity for stakeholders in the industry. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Radiopharmaceuticals Market Application Insights** The Application segment of the South Korea Radiopharmaceuticals Market plays a critical role in the healthcare landscape, demonstrating expansive growth potential across various fields, including Neurology, Cardiology, and Oncology. The South Korean healthcare system is increasingly integrating advanced imaging techniques, with radiopharmaceuticals being central to the early diagnosis and treatment monitoring of neurological disorders, cardiovascular diseases, and cancers. Neurology, for instance, leverages these agents for determining brain function, significantly enhancing patient management in conditions such as Alzheimer’s and Parkinson’s diseases. In Cardiology, the use of radiopharmaceuticals facilitates practical assessment of myocardial perfusion, which is vital for diagnosing coronary artery disease. Oncology remains a key driver, utilizing targeted radiopharmaceutical therapies for various malignancies, thereby personalizing treatment and improving patient outcomes. The 'Others' category, representing various lesser-known applications, also contributes to the diversity and adaptability of the market, aligning with South Korea's emphasis on innovative healthcare solutions. Overall, the South Korea Radiopharmaceuticals Market is shaped by technological advancements and population health trends, fostering substantial opportunities for market growth and segmentation advancements in the coming years. ## **South Korea Radiopharmaceuticals Market Key Players and Competitive Insights** The South Korea Radiopharmaceuticals Market is characterized by a blend of advanced technological capabilities and a growing demand for precision medicine. As a crucial segment of the healthcare industry, this market addresses the need for therapies and diagnostic procedures, particularly in fields like oncology and cardiology. The competition within this sector is dynamic, with companies striving for innovation in the development and delivery of radiopharmaceutical agents.  Factors such as regulatory support, increased funding for research and development, and collaborations between academia and industry players are key elements driving the competitive landscape. The focus is primarily on enhancing the efficacy of diagnostic imaging and treatment while also navigating complexities associated with production, distribution, and regulatory compliance in South Korea.KHIDI stands out as a significant player within the South Korea Radiopharmaceuticals Market, bolstered by its commitment to improving healthcare through innovation and research initiatives.  The organization plays a pivotal role in fostering the development of radiopharmaceutical technologies by coordinating efforts between government, industry, and academia. KHIDI’s strength lies in its deep understanding of the local market dynamics and regulatory environment, enabling it to offer relevant support and resources for radiopharmaceutical development. The entity's engagement in various public-private partnerships encourages a collaborative approach, which not only enhances its credibility but also facilitates advancements in radiopharmaceutical technologies tailored for the South Korean market.  The organization’s initiatives significantly contribute to a more robust healthcare framework that prioritizes patient safety and treatment efficacy.Posco Holdings is another noteworthy entity that has carved out a niche in the South Korea Radiopharmaceuticals Market through its innovative solutions and technological advancements. The company has been actively involved in developing key products and services that include diagnostic and therapeutic agents, catering specifically to the needs of the South Korean healthcare landscape. Posco Holdings has established a strong market presence by leveraging its expertise in materials science and engineering, applying this knowledge to enhance the quality and effectiveness of radiopharmaceutical offerings.  Strengthened by strategic mergers and acquisitions, the company has successfully expanded its portfolio and operational capabilities, positioning itself as a competitive force in the sector. The focus on research and development ensures that Posco Holdings remains at the forefront of technological innovations, ultimately leading to improved patient care and outcomes in the South Korean healthcare ecosystem. ### **Key Companies in the South Korea Radiopharmaceuticals Market Include** ## **South Korea Radiopharmaceuticals Market Industry Developments** Recent developments in the South Korea Radiopharmaceuticals Market indicate a growth-driven environment, primarily attributed to ongoing innovations and regulatory support. Companies like KHIDI and Korea Atomic Energy Research Institute are pushing advancements in the field while ensuring compliance with national health policies. In terms of market dynamics, Posco Holdings and Ilyang Pharmaceutical are notably expanding their portfolios to optimize production capabilities and enhance product offerings. The market has witnessed a significant increase in demand for targeted therapies, bolstered by collaborations among companies such as Daiichi Sankyo and Taejoon Pharmaceutical, focusing on integrating advanced diagnostics with therapeutics.  Additionally, mergers and acquisitions are shaping the landscape; for example, in July 2023, Alphamed acquired a key division of Nautilus Biomedical, expanding its radiopharmaceutical capabilities. The market's valuation has been affected positively by these strategic moves, contributing to an encouraging outlook for innovations in diagnostic imaging. Over the last 2-3 years, significant advancements have included the launch of innovative radioisotopes and the establishment of specialized production facilities to meet escalating demand from healthcare institutions across South Korea. ## **South Korea Radiopharmaceuticals Market Segmentation Insights** ## Market Drivers ### Rising Incidence of Cancer The rising incidence of cancer is a critical driver for the Global South Korea Radiopharmaceuticals Market Industry. With cancer rates steadily increasing, there is an urgent need for effective diagnostic and therapeutic solutions. Radiopharmaceuticals, particularly those used in targeted therapies, are gaining traction due to their ability to deliver localized treatment while minimizing systemic side effects. This trend is expected to contribute to a compound annual growth rate of 9.81% from 2025 to 2035, reflecting the industry's responsiveness to the growing healthcare demands associated with cancer management. ### Regulatory Support and Investment The Global South Korea Radiopharmaceuticals Market Industry benefits from supportive regulatory frameworks that encourage research and development. Government initiatives aimed at fostering innovation in the healthcare sector have led to increased funding for radiopharmaceutical projects. This regulatory environment facilitates faster approval processes for new products, thereby accelerating their entry into the market. Additionally, public-private partnerships are emerging to enhance the development of novel radiopharmaceuticals. Such collaborative efforts may lead to a projected market growth to 3500 USD Million by 2035, indicating a favorable landscape for stakeholders in the industry. ### Growing Demand for Diagnostic Imaging The Global South Korea Radiopharmaceuticals Market Industry experiences a robust demand for diagnostic imaging techniques, particularly in oncology and cardiology. The increasing prevalence of chronic diseases necessitates advanced imaging solutions, which radiopharmaceuticals provide. In 2024, the market is projected to reach 1250 USD Million, driven by innovations in PET and SPECT imaging technologies. Furthermore, the integration of radiopharmaceuticals in personalized medicine enhances diagnostic accuracy, thereby attracting healthcare providers. As the population ages, the need for effective diagnostic tools is likely to escalate, suggesting a sustained growth trajectory for the industry. ### Increasing Awareness of Nuclear Medicine There is a growing awareness of the benefits of nuclear medicine among healthcare professionals and patients, which is positively influencing the Global South Korea Radiopharmaceuticals Market Industry. Educational initiatives and training programs are being implemented to enhance understanding of radiopharmaceutical applications in diagnostics and therapy. This increased awareness is likely to drive demand for radiopharmaceuticals, as more healthcare providers recognize their potential in improving patient care. As the market evolves, the integration of radiopharmaceuticals into routine clinical practice may become more prevalent, further contributing to the industry's growth. ### Advancements in Radiopharmaceutical Technology Technological advancements play a pivotal role in shaping the Global South Korea Radiopharmaceuticals Market Industry. Innovations in radiotracers and production techniques enhance the efficacy and safety of radiopharmaceuticals. For instance, the development of targeted radiopharmaceuticals allows for more precise treatment options, which could lead to improved patient outcomes. The industry is witnessing a shift towards automated production systems, ensuring consistent quality and compliance with regulatory standards. These advancements not only improve the therapeutic index of radiopharmaceuticals but also expand their applications across various medical fields, potentially increasing market value significantly by 2035. ## Future Outlook The South Korea Radiopharmaceuticals Market is projected to grow at a 9.81% CAGR from 2025 to 2035, driven by advancements in diagnostic imaging and increasing cancer prevalence. **New opportunities:** - Invest in AI-driven radiopharmaceutical development for [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937). Expand partnerships with hospitals for integrated diagnostic solutions. Leverage regulatory incentives for innovative product launches in oncology. By 2035, the South Korea Radiopharmaceuticals Market is poised for robust growth, reflecting advancements and increased demand. ## Segment Insights ### Radiopharmaceuticals Market Type Insights The South Korea Radiopharmaceuticals Market is characterized by its significant segmentation into Diagnostic and Therapeutic categories, each playing a crucial role in the overall healthcare landscape. Diagnostic radiopharmaceuticals are widely utilized in various imaging techniques, helping healthcare professionals identify diseases at early stages, which is vital for effective treatment initiation. This category typically includes compounds designed for nuclear imaging, facilitating the visualization of physiological and biochemical processes in living organisms.  The increasing prevalence of chronic diseases in South Korea has necessitated enhanced diagnostic tools, pushing the demand for radiopharmaceuticals in imaging procedures. Meanwhile, the Therapeutic segment of the South Korea Radiopharmaceuticals Market represents an equally vital area, focusing on treating ailments through targeted radionuclide therapy. Such therapies leverage the unique properties of radioactive isotopes to deliver precise doses of radiation to diseased cells, often resulting in lesser side effects compared to traditional treatment modalities.  The growth of personalized medicine has catalyzed the development and acceptance of therapeutic radiopharmaceuticals, particularly for oncology applications. With the rise in cancer diagnoses in South Korea, the significance of these products continues to grow, driven by the efficacy of radiopharmaceuticals in providing effective treatment options. Moreover, both segments are supported by robust advancements in radiochemistry and nuclear medicine technologies, positioning South Korea as a key player in the global radiopharmaceuticals landscape. Government initiatives promoting research and development alongside collaborative efforts between academic institutions and pharmaceutical companies are further driving innovations within the market.  ### Radiopharmaceuticals Market Application Insights The Application segment of the South Korea Radiopharmaceuticals Market plays a critical role in the healthcare landscape, demonstrating expansive growth potential across various fields, including Neurology, Cardiology, and Oncology. The South Korean healthcare system is increasingly integrating advanced imaging techniques, with radiopharmaceuticals being central to the early diagnosis and treatment monitoring of neurological disorders, cardiovascular diseases, and cancers. Neurology, for instance, leverages these agents for determining brain function, significantly enhancing patient management in conditions such as Alzheimer’s and Parkinson’s diseases. In Cardiology, the use of radiopharmaceuticals facilitates practical assessment of myocardial perfusion, which is vital for diagnosing coronary artery disease. Oncology remains a key driver, utilizing targeted radiopharmaceutical therapies for various malignancies, thereby personalizing treatment and improving patient outcomes. The 'Others' category, representing various lesser-known applications, also contributes to the diversity and adaptability of the market, aligning with South Korea's emphasis on innovative healthcare solutions. Overall, the South Korea Radiopharmaceuticals Market is shaped by technological advancements and population health trends, fostering substantial opportunities for market growth and segmentation advancements in the coming years. ## Competitive Benchmarking The South Korea Radiopharmaceuticals Market is characterized by a blend of advanced technological capabilities and a growing demand for [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925). As a crucial segment of the [healthcare industry](https://www.marketresearchfuture.com/reports/healthcare-industry-68323), this market addresses the need for therapies and diagnostic procedures, particularly in fields like oncology and cardiology. The competition within this sector is dynamic, with companies striving for innovation in the development and delivery of radiopharmaceutical agents.  Factors such as regulatory support, increased funding for research and development, and collaborations between academia and industry players are key elements driving the competitive landscape. The focus is primarily on enhancing the efficacy of diagnostic imaging and treatment while also navigating complexities associated with production, distribution, and regulatory compliance in South Korea.KHIDI stands out as a significant player within the South Korea Radiopharmaceuticals Market, bolstered by its commitment to improving healthcare through innovation and research initiatives.  The organization plays a pivotal role in fostering the development of radiopharmaceutical technologies by coordinating efforts between government, industry, and academia. KHIDI’s strength lies in its deep understanding of the local market dynamics and regulatory environment, enabling it to offer relevant support and resources for radiopharmaceutical development. The entity's engagement in various public-private partnerships encourages a collaborative approach, which not only enhances its credibility but also facilitates advancements in radiopharmaceutical technologies tailored for the South Korean market.  The organization’s initiatives significantly contribute to a more robust healthcare framework that prioritizes patient safety and treatment efficacy.Posco Holdings is another noteworthy entity that has carved out a niche in the South Korea Radiopharmaceuticals Market through its innovative solutions and technological advancements. The company has been actively involved in developing key products and services that include diagnostic and therapeutic agents, catering specifically to the needs of the South Korean healthcare landscape. Posco Holdings has established a strong market presence by leveraging its expertise in materials science and engineering, applying this knowledge to enhance the quality and effectiveness of radiopharmaceutical offerings.  Strengthened by strategic mergers and acquisitions, the company has successfully expanded its portfolio and operational capabilities, positioning itself as a competitive force in the sector. The focus on research and development ensures that Posco Holdings remains at the forefront of technological innovations, ultimately leading to improved patient care and outcomes in the South Korean healthcare ecosystem. ## Recent News & Developments Recent developments in the South Korea Radiopharmaceuticals Market indicate a growth-driven environment, primarily attributed to ongoing innovations and regulatory support. Companies like KHIDI and Korea Atomic Energy Research Institute are pushing advancements in the field while ensuring compliance with national health policies. In terms of market dynamics, Posco Holdings and Ilyang Pharmaceutical are notably expanding their portfolios to optimize production capabilities and enhance product offerings. The market has witnessed a significant increase in demand for targeted therapies, bolstered by collaborations among companies such as Daiichi Sankyo and Taejoon Pharmaceutical, focusing on integrating advanced diagnostics with therapeutics.  Additionally, mergers and acquisitions are shaping the landscape; for example, in July 2023, Alphamed acquired a key division of Nautilus Biomedical, expanding its radiopharmaceutical capabilities. The market's valuation has been affected positively by these strategic moves, contributing to an encouraging outlook for innovations in diagnostic imaging. Over the last 2-3 years, significant advancements have included the launch of innovative radioisotopes and the establishment of specialized production facilities to meet escalating demand from healthcare institutions across South Korea. ## Report Scope | Report Attribute/Metric Source: | Details | | --- | --- | | MARKET SIZE 2024 | 1250 (USD Million) | | MARKET SIZE 2025 | USD Million | | MARKET SIZE 2035 | 3500 (USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.81% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | MARKET FORECAST PERIOD | 2025 - 2035 | | HISTORICAL DATA | 2019 - 2024 | | MARKET FORECAST UNITS | USD Billion | | KEY COMPANIES PROFILED | KHIDI, Posco Holdings, Ilyang Pharmaceutical, PTG Energy, Daiichi Sankyo, Taejoon Pharmaceutical, Korea Atomic Energy Research Institute, Alphamed, Philips Healthcare, Korea Radioisotope Association, Nautilus Biomedical, Hanmi Pharmaceutical, Bioscience Institute, Lantheus, CURE Pharmaceuticals | | SEGMENTS COVERED | Type, Application | | KEY MARKET OPPORTUNITIES | Aging population increasing demand, Advancements in diagnostic imaging, Growth in cancer treatment options, Expansion of nuclear medicine facilities, Government investment in healthcare technologies | | KEY MARKET DYNAMICS | growing cancer prevalence , technological advancements , increasing elderly population , expanding diagnostic imaging demand , government support and funding | | COUNTRIES COVERED | South Korea | ## Frequently Asked Questions **Q: What is the expected market size of the South Korea Radiopharmaceuticals Market in 2024?** A: The South Korea Radiopharmaceuticals Market is expected to be valued at 0.18 billion USD in 2024. **Q: What is the projected market size for the South Korea Radiopharmaceuticals Market by 2035?** A: By 2035, the South Korea Radiopharmaceuticals Market is anticipated to reach a valuation of 0.42 billion USD. **Q: What is the expected CAGR for the South Korea Radiopharmaceuticals Market from 2025 to 2035?** A: The expected CAGR for the South Korea Radiopharmaceuticals Market from 2025 to 2035 is 8.18%. **Q: What is the projected value of the Diagnostic segment in the South Korea Radiopharmaceuticals Market by 2035?** A: The Diagnostic segment is expected to grow to 0.22 billion USD by 2035. **Q: What will the market value of the Therapeutic segment be in 2035?** A: The Therapeutic segment of the South Korea Radiopharmaceuticals Market is projected to be valued at 0.2 billion USD by 2035. **Q: Who are the major players in the South Korea Radiopharmaceuticals Market?** A: Key players include KHIDI, Ilyang Pharmaceutical, and Posco Holdings. **Q: Is there growth potential in the South Korea Radiopharmaceuticals Market?** A: Yes, the market exhibits significant growth potential due to increasing applications in medical diagnostics and treatment. **Q: What are the key applications driving the growth of the South Korea Radiopharmaceuticals Market?** A: The key applications include both Diagnostic imaging and Therapeutic treatments. **Q: What are some challenges faced by the South Korea Radiopharmaceuticals Market?** A: Challenges include regulatory hurdles and high production costs affecting market expansion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-radiopharmaceuticals-market-43909*